• Teleflex awarded Central Venous Access contract from Vizient

    WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has been awarded a contract for the supply of Central Venous Access products from Vizient, Inc., the nation’s largest member-driven healthcare performance improvement company. The agreement is effective starting August 1, 2022.

    Vizient provides solutions and services that improve the delivery of high-value care by aligning cost, quality, and market performance for more than 50% of the nation’s acute care providers. This includes 97% of the nation’s academic medical centers, and more than 20% of ambulatory care providers. Vizient provides expertise, analytics, and advisory services, as well as a contract portfolio that represents more than $130 billion in annual purchasing volume to improve patient outcomes and lower costs.

    This new agreement allows Vizient members to take advantage of special pricing and terms pre-negotiated by Vizient for Central Venous Access products.

    “As the market leader in Central Venous Catheters (CVCs)1, we are pleased to offer Vizient members one of the broadest portfolios of central access products available,” said Lisa Kudlacz, President and General Manager, Teleflex Vascular. “Our Arrow® Brand of vascular access products are designed to equally benefit clinicians and patients, help protect against vascular access related complications like infection, thrombosis, and tip malposition, and help clinicians follow independent third-party vascular access guidelines.”

    Teleflex, through its Arrow® Brand of CVC products, has been innovating for more than four decades to help healthcare providers optimize patient outcomes, minimize the risk of central line-associated infections (CLABSI), and efficiently streamline insertion procedures2-5.

    The group purchasing agreement includes access to Teleflex Arrowg+ard Blue Plus® CVCs and Arrow® ErgoPack® Complete Systems.

    Antimicrobial Arrowg+ard Blue Plus® CVCs are the only full-spectrum antimicrobial CVCs that protect against both gram-positive and gram-negative bacteria, fungi, and demonstrate a 67-100% reduction in CLABSI2-5.

    Combined with antimicrobial Arrowg+ard Blue Plus® CVCs, Arrow® ErgoPack® Complete Systems help make it easy to:

    • Standardize vascular access across a system
    • Maintain a high standard of patient care
    • Control costs and risks from infections6

    Arrow® ErgoPack® Complete Systems help clinicians comply with third-party guideline recommendations7-10, including:

    • CDC Category 1A &1B Recommendations
    • SHEA Guidelines
    • INS Standards of Practice
    • OSHA Bloodborne Pathogens Standard

    About Teleflex Incorporated
    Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

    Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®, QuikClot®, Rüsch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose.

    Forward-Looking Statements
    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

    References

    1. IMS Data. Data based on 2021 Q4 Total Acute CVC market unit share for Teleflex. 2021.
    2. Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a Second-Generation Venous Catheter Impregnated with Chlorhexidine and Silver Sulfadiazine of Central Catheter-Related Infections. Ann Intern Medicine. 2005; 143: 570-80. Sponsored by Arrow (Teleflex).
    3. Lorente L, Lecuona M, Jimenez A, et al. Chlorhexidine-silver sulfadiazine-impregnated venous catheters save costs. American Journal of Infection Control. 2014; 42: 321-4.
    4. Lorente L, Lecuona M, Jimenez A, et al. Cost/benefit analysis of chlorhexidine-silver sulfadiazine-impregnated venous catheters for femoral access. American Journal of Infection Control. 2014; 42: 1130-2.
    5. Lorente, L, et al. Chlorhexidine-silver sulfadiazine-impregnated venous catheters are efficient even at subclavian sites without tracheostomy. American journal of infection control. 2016; 44(12): 1526-29. Zimlichman, E, et al.
    6. Abouleish, YZ, Oldfield EC, Marik PE. Comparison of central-line–associated bloodstream infections between central venous catheters lined by combined chlorhexidine and silver sulfadiazine versus silver ionotrophes alone: A before–after–before retrospective study. Infection Control & Hospital Epidemiology (2020): 1-3.
    7. O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011 (Revised 2017). 2. Atlanta, GA: Centers for Disease Control and Prevention; 2017.
    8. Buetti, N., Marschall, J., Drees, M., Fakih, M., Hadaway, L., Maragakis, L., Mermel, L. (2022). Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update. Infection Control & Hospital Epidemiology, 1-17. doi:10.1017/ice.2022.87.
    9. Gorski, Lisa A., et al. "Infusion therapy standards of practice." Journal of Infusion Nursing, 44.1S (2021): S1-S224.
    10. Occupational Safety & Health Administration Regulations (Standards – 29 CFR). Part 1910.1030: Bloodborne pathogens. Occupational Safety & Health Administration Web site. https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030. Accessed on February 12, 2020.

    Rx only
    Contraindication: The Arrowg+ard Blue Plus ®  CVC is contraindicated for patients with known hypersensitivity to chlorhexidine and silver sulfadiazine and/or sulfa drugs.

    Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Plus, Deknatel, ErgoPack, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks or registered trademarks of their respective owners.
    © 2022 Teleflex Incorporated. All rights reserved. MC-007976

    Contacts:
    Teleflex Incorporated:
    Lawrence Keusch
    Vice President, Investor Relations and Strategy Development

    John Hsu, CFA
    Vice President, Investor Relations

    investors.teleflex.com
    610-948-2836 

    Source:

    Read original here: https://investors.teleflex.com/news/news-details/2022/Teleflex-awarded-Central-Venous-Access-contract-from-Vizient/default.aspx

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details